search
Back to results

A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy

Primary Purpose

Duchenne Muscular Dystrophy

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Visit frequency
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Duchenne Muscular Dystrophy

Eligibility Criteria

0 Years - undefined (Child, Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Chinese male patients with any age, diagnosed with DMD. Diagnosis must be confirmed in subject's medical history and by genetic testing obtained during routine clinical care for diagnostic purposes as reported from an appropriate regulated laboratory using a clinically validated genetic test (genetic testing is not provided by the sponsor).
  2. Subjects who are >=4 years old must be receiving glucocorticosteroids for a minimum of 6 months prior to signing informed consent. There should be no significant change (<0.2 mg/kg) in dosage or dose regimen (not related to body weight change) for at least 3 months immediately prior to signing the informed consent. Subjects who are aged >4 years will be exempt from this requirement; those not taking GC will be eligible if the initiation of GC treatment in these subjects is considered inappropriate in the opinion of Investigators.

Exclusion Criteria:

  1. Any injury which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date.
  2. Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary, cardiac, and cognitive diseases.
  3. Subjects >=4 years old who have not completed the varicella vaccination.
  4. Participation in other studies involving investigational drug(s) for a minimum of 90 days prior to signing the informed consent and/or during study participation.

Sites / Locations

  • Children's Hospital of Chongqing Medical University
  • Children's Hospital of Chongqing Medical University (Liangjiang Branch)
  • The First Affiliated Hospital Of Fujian Medical University
  • Peking University First Hospital
  • Beijing Children's Hospital, Capital Medical University
  • Huashan Hospital, Fudan University
  • Affiliated children's hospital of fudan university
  • Children's Hospital of Fudan University

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Study arm

Arm Description

All subjects in this study will be observed for 24-30 months.

Outcomes

Primary Outcome Measures

Time to life altering clinical milestones due to DMD disease progression - failure to walk
Time to life altering clinical milestones due to DMD disease progression - failure to stand
Time to life altering clinical milestones due to DMD disease progression - failure to self feed
Change from Baseline in timed motor functions for ambulatory subjects - rise from floor (supine to stand)
Change from Baseline in timed motor functions for ambulatory subjects - 10 meter walk/run
Change from Baseline in clinical evaluator determined scales - Northstar Ambulatory Assessment
The Northstar Ambulatory Assessment will be performed in ambulatory children >=3 years old
Change from Baseline in clinical evaluator determined scales - Performance of Upper Limb 2.0
The Performance of Upper Limb 2.0 will be administered in subjects >=10 years old.
Change from Baseline in strength of muscle groups - knee extension
Change from Baseline in strength of muscle groups - elbow flexion
Change from Baseline in strength of muscle groups - elbow extension
Change from Baseline in strength of muscle groups - shoulder abduction.
Change from Baseline in pulmonary function tests - Percent predicted Forced Vital Capacity (%pFVC)
Change from Baseline in pulmonary function tests - Forced Expiratory Volume in one Second
Change from Baseline in pulmonary function tests - Maximum Inspiratory Pressure
Change from Baseline in pulmonary function tests - Maximum Expiratory Pressure
Change from Baseline in pulmonary function tests - Peak cough flow
Change from Baseline in range of motion (ROM) at bilateral ankles and elbows
Change from Baseline in left ventricular ejection fraction (LVEF)
Change from Baseline in Wechsler Intelligence Scale for Children (WISC) score in ambulatory subjects aged >=6 years to <=16 years
The WISC is individually administered intelligence test for children between ages of 6 and 16. It generates a Full Scale Intelligence Quotient.

Secondary Outcome Measures

Proportion of subjects with mutation of large deletion
Proportion of subjects with mutation of large duplication
Proportion of subjects with mutation of small insertion
Proportion of subjects with mutation of small deletion
Proportion of subjects with mutation of point mutation
Proportion of subjects with mutations involving key high frequency mutation sites
Change from Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) score
The Pediatric Outcomes Data Collection Instrument is a patient-reported assessment of musculoskeletal health intended for use in children and adolescents.
Change from Baseline in EuroQoL 5 Dimension 3 Level (EQ-5D-3L)
The EQ-5D-3L is instrument measuring health-related quality of life for patients >=16 years old.
Change from Baseline in EuroQoL 5 Dimension Youth (EQ-5D-Y)
EQ-5D-Y is a generic instrument measuring health-related quality of life in children and adolescents younger than 16 years old and able to read and complete the questionnaire.
Change from Baseline in Healthcare Resource Utilization (HRU) score
The result collection is based on the HRU questionnaire.
Change from Baseline in Work Productivity and Activity Impairment Questionnaire adapted for Caregiving (WPAI:CG) impairment scores
WPAI:CG will measure the impact of a subject with DMD on a caregiver's work productivity and regular activities. It will be administered as questionnaire.

Full Information

First Posted
November 15, 2018
Last Updated
April 3, 2023
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT03760029
Brief Title
A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy
Official Title
A NATURAL HISTORY STUDY IN CHINESE MALE PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
July 24, 2019 (Actual)
Primary Completion Date
March 21, 2023 (Actual)
Study Completion Date
March 21, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a multicenter, prospective, single cohort study designed to describe the natural history of DMD in Chinese male patients. A total of approximately 330 subjects will be enrolled with the target number of subjects in each group as below: Group 1, Ambulatory subjects aged <6 years, approximately 100 subjects; Group 2, Ambulatory subjects aged >=6 years, approximately 180 subjects; Group 3, Non-ambulatory subjects, approximately 50 subjects. Subjects will visit sites every 6 months. Each subject will be observed for at least 24 months. All subjects will remain enrolled until the study completion date, such that some will have data collected after Month 24. Subjects, who complete Visit 5/Month 24 at least 6 months prior to study completion, will be asked to complete an additional visit at Month 30.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Duchenne Muscular Dystrophy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
312 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Study arm
Arm Type
Other
Arm Description
All subjects in this study will be observed for 24-30 months.
Intervention Type
Other
Intervention Name(s)
Visit frequency
Intervention Description
All subjects need to visit sites more frequently than in routine clinical practice.
Primary Outcome Measure Information:
Title
Time to life altering clinical milestones due to DMD disease progression - failure to walk
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Time to life altering clinical milestones due to DMD disease progression - failure to stand
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Time to life altering clinical milestones due to DMD disease progression - failure to self feed
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in timed motor functions for ambulatory subjects - rise from floor (supine to stand)
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in timed motor functions for ambulatory subjects - 10 meter walk/run
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in clinical evaluator determined scales - Northstar Ambulatory Assessment
Description
The Northstar Ambulatory Assessment will be performed in ambulatory children >=3 years old
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in clinical evaluator determined scales - Performance of Upper Limb 2.0
Description
The Performance of Upper Limb 2.0 will be administered in subjects >=10 years old.
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in strength of muscle groups - knee extension
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in strength of muscle groups - elbow flexion
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in strength of muscle groups - elbow extension
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in strength of muscle groups - shoulder abduction.
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in pulmonary function tests - Percent predicted Forced Vital Capacity (%pFVC)
Time Frame
Change from baseline, 12, 24, 30 Months
Title
Change from Baseline in pulmonary function tests - Forced Expiratory Volume in one Second
Time Frame
Change from baseline, 12, 24, 30 Months
Title
Change from Baseline in pulmonary function tests - Maximum Inspiratory Pressure
Time Frame
Change from baseline, 12, 24, 30 Months
Title
Change from Baseline in pulmonary function tests - Maximum Expiratory Pressure
Time Frame
Change from baseline, 12, 24, 30 Months
Title
Change from Baseline in pulmonary function tests - Peak cough flow
Time Frame
Change from baseline, 12, 24, 30 Months
Title
Change from Baseline in range of motion (ROM) at bilateral ankles and elbows
Time Frame
Change from baseline, 6, 12, 18, 24, 30 Months
Title
Change from Baseline in left ventricular ejection fraction (LVEF)
Time Frame
Change from baseline, 12, 24, 30 Months
Title
Change from Baseline in Wechsler Intelligence Scale for Children (WISC) score in ambulatory subjects aged >=6 years to <=16 years
Description
The WISC is individually administered intelligence test for children between ages of 6 and 16. It generates a Full Scale Intelligence Quotient.
Time Frame
Chang from baseline, 24 Months
Secondary Outcome Measure Information:
Title
Proportion of subjects with mutation of large deletion
Time Frame
Baseline
Title
Proportion of subjects with mutation of large duplication
Time Frame
Baseline
Title
Proportion of subjects with mutation of small insertion
Time Frame
Baseline
Title
Proportion of subjects with mutation of small deletion
Time Frame
Baseline
Title
Proportion of subjects with mutation of point mutation
Time Frame
Baseline
Title
Proportion of subjects with mutations involving key high frequency mutation sites
Time Frame
Baseline
Title
Change from Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) score
Description
The Pediatric Outcomes Data Collection Instrument is a patient-reported assessment of musculoskeletal health intended for use in children and adolescents.
Time Frame
Baseline, 12, 24, 30 Months
Title
Change from Baseline in EuroQoL 5 Dimension 3 Level (EQ-5D-3L)
Description
The EQ-5D-3L is instrument measuring health-related quality of life for patients >=16 years old.
Time Frame
Baseline, 12, 24, 30 Months
Title
Change from Baseline in EuroQoL 5 Dimension Youth (EQ-5D-Y)
Description
EQ-5D-Y is a generic instrument measuring health-related quality of life in children and adolescents younger than 16 years old and able to read and complete the questionnaire.
Time Frame
Baseline, 12, 24, 30 Months
Title
Change from Baseline in Healthcare Resource Utilization (HRU) score
Description
The result collection is based on the HRU questionnaire.
Time Frame
Baseline, 12, 24, 30 Months
Title
Change from Baseline in Work Productivity and Activity Impairment Questionnaire adapted for Caregiving (WPAI:CG) impairment scores
Description
WPAI:CG will measure the impact of a subject with DMD on a caregiver's work productivity and regular activities. It will be administered as questionnaire.
Time Frame
Baseline, 12, 24, 30 Months

10. Eligibility

Sex
Male
Gender Based
Yes
Minimum Age & Unit of Time
0 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chinese male patients with any age, diagnosed with DMD. Diagnosis must be confirmed in subject's medical history and by genetic testing obtained during routine clinical care for diagnostic purposes as reported from an appropriate regulated laboratory using a clinically validated genetic test (genetic testing is not provided by the sponsor). Subjects who are >=4 years old must be receiving glucocorticosteroids for a minimum of 6 months prior to signing informed consent. There should be no significant change (<0.2 mg/kg) in dosage or dose regimen (not related to body weight change) for at least 3 months immediately prior to signing the informed consent. Subjects who are aged >4 years will be exempt from this requirement; those not taking GC will be eligible if the initiation of GC treatment in these subjects is considered inappropriate in the opinion of Investigators. Exclusion Criteria: Any injury which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date. Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary, cardiac, and cognitive diseases. Subjects >=4 years old who have not completed the varicella vaccination. Participation in other studies involving investigational drug(s) for a minimum of 90 days prior to signing the informed consent and/or during study participation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Children's Hospital of Chongqing Medical University
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400014
Country
China
Facility Name
Children's Hospital of Chongqing Medical University (Liangjiang Branch)
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
401122
Country
China
Facility Name
The First Affiliated Hospital Of Fujian Medical University
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350005
Country
China
Facility Name
Peking University First Hospital
City
Beijing
ZIP/Postal Code
100034
Country
China
Facility Name
Beijing Children's Hospital, Capital Medical University
City
Beijing
ZIP/Postal Code
100045
Country
China
Facility Name
Huashan Hospital, Fudan University
City
Shanghai
ZIP/Postal Code
200040
Country
China
Facility Name
Affiliated children's hospital of fudan university
City
Shanghai
ZIP/Postal Code
201102
Country
China
Facility Name
Children's Hospital of Fudan University
City
Shanghai
ZIP/Postal Code
201102
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Links:
URL
https://pmiform.com/clinical-trial-info-request?StudyID=C3391004
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy

We'll reach out to this number within 24 hrs